Table 2. Comparison on rosuvastatin and atorvastatin beteween the groups.
| Atorvastatin | Rosuvastatin | PT0 | PT12 | |||
|---|---|---|---|---|---|---|
| Baseline (n = 16) | 12 months (n = 16) | Baseline (n = 43) | 12 months (n = 39) | |||
| Creatinine (mg/dl) | 1.31 ± 0.47 | 1.19 ± 0.29 | 1.41 ± 0.46 | 1.26 ± 0.50 | 0.44 | 0.62 |
| CKD EPI (ml/min/1.73 m2) | 64.9 ± 22.6 | 68.7 ± 15.0 | 61.0 ± 20.6 | 70.2 ± 23.1 | 0.52 | 0.82 |
| Total cholesterol (mg/dl) | 203.9 ± 43.1 | 153.6 ± 41.1 | 216.2 ± 45.8 | 44.6 ± 13.9 | 0.35 | 0.45 |
| HDL-c (mg/dl) | 51.6 ± 15.4 | 46.8 ± 10.2 | 53.5 ± 16.8 | 44.6 ± 13.9 | 0.69 | 0.56 |
| LDL-c (mg/dl) | 110.8 ± 31.3 | 78.2 ± 35.6 | 119.6 ± 35.7 | 90.8 ± 39.6 | 0.40 | 0.28 |
| Triglycerides (mg/dl) | 187 (130–234) | 127 (91–184) | 179 (124–246) | 164 (90–213) | 0.98 | 0.33 |
| CAC score (AU) | 0 (0–8.7) | 0 (0–20) | 0 (0–74) | 0 (0–79.7) | 0.19 | 0.43 |
| ΔCAC relative | 0 (0–48) | 0 (0–23) | 0.49 | |||
Mean ± standard deviation, median (interquartiles)
HDL-c—HDL cholesterol; LDL-c—LDL cholesterol; CAC—coronary calcification.